Immunovant

Also Clin3 thyroid eye disease, Clin2b inflammatory demyelinating polyneuropathy, Clin2 Graves disease; IMVT-1402 Clin0 autoimmune diseases

Immunovant is creating therapies for autoimmune diseases. Autoimmune diseases arise when a patient's immune system incorrectly identifies healthy cells as harmful and thus generates autoantibodies. FcRn is a protein receptor that prevents degradation of autoantibodies. Immunovant’s lead product, IMVT-1401, is a human anti-FcRn monoclonal antibody that can be delivered via subcutaneous injection. IMVT-1401 inhibits and enhances degradation of FcRn, thereby allowing degradation of autoantibodies that cause autoimmune disease. Immunovant plans to test IMVT-1401 against a variety of indications, including thyroid eye disease and Myasthenia Gravis.